Changing the Properties of Multipotent Mesenchymal Stromal Cells by IFNγ Administration
- Авторлар: Petinati N.1, Kapranov N.1, Bigil’deev A.1, Popova M.1, Davydova Y.1, Gal’tseva I.1, Drize N.1, Kuz’mina L.1, Parovichnikova E.1, Savchenko V.1
-
Мекемелер:
- Hematology Research Center, Ministry of Health Care of the Russian Federation
- Шығарылым: Том 163, № 2 (2017)
- Беттер: 230-234
- Бөлім: Microbiology and Immunology
- URL: https://journals.rcsi.science/0007-4888/article/view/238778
- DOI: https://doi.org/10.1007/s10517-017-3773-3
- ID: 238778
Дәйексөз келтіру
Аннотация
We studied changes in the population of human multipotent mesenchymal stromal cells activated by IFNγ. The cells were cultured under standard conditions; IFNγ was added in various concentrations for 4 h or over 2 passages. It was shown that the total cell production significantly decreased after long-term culturing with IFNγ, but 4-h exposure did not affect this parameter. After 4-h culturing, the expression levels of IDO1, CSF1, and IL-6 increased by 300, 7, and 2.4 times, respectively, and this increase persisted 1 and 2 days after removal of IFNγ from the culture medium. The expression of class I and II MHC (HLA) on cell surface practically did not change immediately after exposure to IFNγ, but during further culturing, HLA-ABC (MHC I) and HLA-DR (MHC II) expression significantly increased, which abolished the immune privilege in these cells, the property allowing clinical use of allogenic multipotent mesenchymal stromal cells. Multipotent mesenchymal stromal cells can suppress proliferation of lymphocytes. The degree of this suppression depends on individual properties of multipotent mesenchymal stromal cell donor. Treatment with IFNγ did not significantly affect the intensity of inhibition of lymphocyte proliferation by these cells.
Авторлар туралы
N. Petinati
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Ресей, Moscow
N. Kapranov
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Ресей, Moscow
A. Bigil’deev
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Ресей, Moscow
M. Popova
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Ресей, Moscow
Yu. Davydova
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Ресей, Moscow
I. Gal’tseva
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Ресей, Moscow
N. Drize
Hematology Research Center, Ministry of Health Care of the Russian Federation
Хат алмасуға жауапты Автор.
Email: ndrize@yandex.ru
Ресей, Moscow
L. Kuz’mina
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Ресей, Moscow
E. Parovichnikova
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Ресей, Moscow
V. Savchenko
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Ресей, Moscow